Tetanus Toxoid

Overview

Tetanus is caused by tetanospasmin, a 150 kDa zinc-dependent metalloprotease AB-toxin produced by Clostridium tetani in anaerobic wound environments. The toxin's light chain cleaves VAMP/synaptobrevin, a key SNARE protein required for vesicle fusion at inhibitory interneurons in the spinal cord and brainstem. Cleavage abolishes glycine and GABA release, producing the characteristic spastic paralysis (lockjaw, risus sardonicus, opisthotonus) with autonomic instability. Tetanus remains lethal in 10–80% of clinical cases without intensive care. Despite effective vaccination, it kills approximately 34,000 people annually (WHO, 2019 estimates), predominantly through neonatal tetanus (unhygienic cord cutting) in low-income countries.

Tetanus toxoid is manufactured by growing C. tetani in liquid culture (e.g., Mueller-Miller medium), harvesting the secreted tetanospasmin, and formalin-inactivating it with 0.2–0.4% formaldehyde at 37 °C for 3–4 weeks. This detoxification alkylates lysine residues in the catalytic site, permanently abolishing enzymatic activity while preserving the immunodominant epitopes of the heavy chain (cell-binding domain, HC) and light chain (enzymatic domain, LC), allowing the immune system to generate anti-toxin antibodies that block neuronal binding and endocytosis. The toxoid is adsorbed onto aluminum hydroxide or aluminum phosphate (alum) adjuvant to create a depot that enhances and prolongs the immune response.

The correlate of protection is an anti-TT IgG titer of ≥0.1 IU/mL (enzyme-linked immunosorbent assay or in-vivo mouse neutralization test) — historically derived from studies showing that serum containing ≥0.01 IU/mL was protective in guinea pigs, with the human clinical threshold conservatively set higher. Titers ≥1.0 IU/mL are associated with long-term protection without booster. Tetanus toxoid is incorporated in multi-antigen formulations: DTaP (pediatric; diphtheria, tetanus, acellular pertussis), DTP (diphtheria, tetanus, whole-cell pertussis; still widely used in LMICs via Pentavalent vaccine), Td (adult-reduced diphtheria + tetanus), and Tdap (adult reduced diphtheria, tetanus, acellular pertussis). Tetanus toxoid alone (TT) is used for maternal immunization in settings without multi-antigen alternatives.

Platform & Antigen Design

TETANUS TOXOID — MECHANISM OF DISEASE PREVENTION
=================================================

  DISEASE MECHANISM (wild-type tetanospasmin):
  C. tetani (anaerobic wound) → tetanospasmin secreted
          │  HC domain binds GT1b ganglioside (motor neuron terminal)
          │  Retrograde axonal transport to spinal cord interneurons
          ▼
  Light chain (Zn²⁺ metalloprotease)
  cleaves VAMP/synaptobrevin (SNARE protein)
          │
          ▼
  SNARE complex fails → vesicle fusion blocked
  → Inhibitory glycine/GABA neurons silenced
          │
          ▼
  Unchecked α-motor neuron firing
  → Spastic paralysis (risus sardonicus, opisthotonus,
    trismus, autonomic instability)

  TOXOID VACCINE PROTECTION:
  Formalin-inactivated tetanospasmin (toxoid)
  + alum adjuvant → IM injection
          │
          ▼
  Anti-TT IgG ≥0.1 IU/mL (seroprotective)
          │
          ▼
  IgG binds HC cell-binding domain → blocks GT1b binding
  IgG neutralizes toxin in serum before neuronal endocytosis
          │
          ▼
  Spinal interneurons protected → no spastic paralysis

  FORMALIN INACTIVATION CHEMISTRY:
  HCHO (0.2–0.4%) + tetanospasmin → 37°C × 3–4 weeks
  → Formaldehyde alkylates Lys (LC active site)
  → Destroys Zn²⁺-metalloprotease activity
  → Preserves HC/LC surface epitopes → immunogenic

1. Fermentation: C. tetani grown anaerobically in protein-free or Mueller-Miller medium; tetanospasmin (150 kDa, A+B structure) secreted into supernatant at peak culture.
2. Purification: Ammonium sulfate precipitation and/or column chromatography concentrate tetanospasmin; quality controlled for toxin units (Lf, flocculation units) before detoxification.
3. Formalin inactivation: 0.2–0.4% formaldehyde at 37 °C for 3–4 weeks alkylates the zinc-binding lysine residues in the LC metalloprotease active site, permanently inactivating enzymatic (VAMP-cleaving) activity while preserving surface immunogenicity.
4. Adsorption: Toxoid adsorbed onto aluminum hydroxide (alum) creates a particulate depot at the injection site, slowing antigen release, enhancing uptake by APCs, and activating the NLRP3 inflammasome for robust adjuvant effect.
5. Antibody neutralization: Anti-TT IgG (primarily targeting HC domain, specifically the receptor-binding HC-C fragment) prevents tetanospasmin binding to GT1b gangliosides on presynaptic motor neuron terminals, neutralizing toxin in the extracellular/vascular compartment before neuronal endocytosis. Once internalized, toxin is no longer accessible to antibody.

Immunogenicity

Clinical Efficacy

Safety Profile

• Rare / Serious Arthus reaction (hyperdose) — Immune-complex (Type III) local reaction at injection site in adults who have received very frequent (excess) boosters with very high pre-existing anti-TT titers. Presents as severe local erythema, edema, induration within 2–8 hours. Prevented by not giving tetanus-containing vaccine more frequently than every 5 years (wound management) or 10 years (routine). Not a concern with standard schedules.
• Rare / Serious Brachial neuritis (neuralgic amyotrophy) — Rare (estimated 1–2/100,000 doses); acute onset shoulder and arm pain with focal weakness/atrophy, mediated by immune-complex deposition or direct nerve inflammation. Onset days to weeks post-vaccination. Resolves in months to years. Risk similar to other protein antigens in susceptible individuals.
• Rare / Serious Anaphylaxis — Very rare; estimated <1–2 per million doses. Observe for 15 minutes post-injection.
• Common Injection-site pain, swelling, redness — Very common (up to 75% of adults); alum depot causes local inflammation and transient tender nodule. Resolves within 48–72 hours. Warm compress recommended.
• Common Systemic — fever, fatigue, myalgia — Low-grade fever (<38.5 °C) in ~5–15% of adults; fatigue and myalgia in 10–25%. More common with Tdap (pertussis component adds reactogenicity) than Td alone. Self-limiting within 24–48 hours.
• Uncommon Nodule at injection site — Persistent, painless nodule from alum depot at deltoid; occurs in ~1–2% if vaccine injected too superficially. Resolves over weeks to months; no treatment required beyond reassurance.
• Rare Extensive limb swelling (DTaP, pre-school dose 4–5) — Transient large local reaction (entire limb swelling) after 4th or 5th DTaP dose in some children; self-limited, related to high anti-TT/anti-PT memory response. Does not recur in subsequent doses; not a contraindication to Td completion.

Administration

Connections

References

• WHO. Tetanus vaccines: WHO position paper — February 2017. Wkly Epidemiol Rec. 2017;92(6):53–76. WHO WER 2017
• Schiavo G, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359(6398):832–835. doi:10.1038/359832a0
• Bleck TP. Tetanus: pathophysiology, management, and prophylaxis. Dis Mon. 1991;37(9):545–603. PMID 1879590
• Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet. 2007;370(9603):1947–1959. doi:10.1016/S0140-6736(07)61261-6
• Borrow R, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001 (TT conjugate antigen model reference). PMID 11328939
• Galazka A, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol. 1995;11(1):95–105. (Immunization program context) PMID 7614259
• Walls T, Hawrami K, Scheifele D. Tetanus and diphtheria toxoids. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 7th ed. Philadelphia: Elsevier; 2018:1036–1065.